# Cancer Immunotherapeutics

> **NIH NIH P30** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2020 · $68,118

## Abstract

Cancer Immunotherapeutics Program
ABSTRACT
The mission of the Cancer Immunotherapeutics (CI) Program is to develop novel immunotherapy interventions
that harness patients’ immune responses for more specific and less toxic cancer therapies, and translate them
into clinical practice. To achieve this goal, the Program has three themes: 1) Develop approaches to enhance
efficacy of adoptive T cell therapy and cancer vaccines; 2) Modulate the tumor microenvironment to enhance
immunotherapy; and 3) Develop novel antibody therapies and imaging modalities. Within each of these themes,
research is ongoing to reduce health disparities within our catchment area. Led by Peter Lee, MD and Hua Yu,
PhD, the CI Program spans basic, translational, and clinical research. To translate discoveries into therapies,
the CI Program receives support from the City of Hope Comprehensive Cancer Center (COHCCC) through the
GMP Manufacturing Core, consisting of three cGMP manufacturing facilities that can produce clinical grade
antibody-based therapeutics and small molecule drugs. Targeted recruits with national prominence have added
both depth and breadth to the program and include Drs. Mingye Feng, Edwin Manuel, Kim Margolin, Laleh
Melstrom, Javier Ogembo, Susanne Warner, Yanghee Woo, and Weiping Zou. The major areas of research
focus in the CI Program are strengthened by extensive collaborations with other investigators at COHCCC as
well as collaborations with investigators at other academic institutions and industry. Sponsored activities include
monthly research meetings, monthly seminars, an annual retreat, and annual pilot funding.
Membership: 21 Program Members representing 7 basic and clinical departments
Publications: 176 total. 18.2% intra-programmatic; 64.8% inter-programmatic; 35.8% inter-institutional
Funding: $4,177,832 peer-reviewed; $2,134,027 of which is NCI funding

## Key facts

- **NIH application ID:** 9849211
- **Project number:** 5P30CA033572-37
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** Peter Poon-Hang Lee
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $68,118
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9849211

## Citation

> US National Institutes of Health, RePORTER application 9849211, Cancer Immunotherapeutics (5P30CA033572-37). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9849211. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*